Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: Efficacy and safety

Journal of Internal Medicine

Volumn 247, Issue 5, 2000, Pages 563-569

  Gavish, D ^a   Leibovitz, E ^a   Shapira, I ^b   Rubinstein, A ^b  

^a WOLFSON MEDICAL CENTER   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Cardiovascular event; Combination therapy; Diabetic dyslipidaemia; Fibrate; Statin

Indexed keywords

BEZAFIBRATE; CHOLESTEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

AGED; ANTILIPEMIC AGENTS; BEZAFIBRATE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; SIMVASTATIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034127122     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2000.00646.x     Document Type: Article

References (28)

1. 1 Panzram G, Zabel LR. Prognosis of diabetes mellitus in a geographically defined population. Diabetologia 1981; 20: 587-91.
2. 2 Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987; 3: 463-524.
3. 3 Laakso M, Ronnemaa T, Lehto S, Puukka P, Kallio V, Pyorala K. Does NIDDM increase the risk for coronary heart disease similarly in both low-and high-risk populations? Diabetologia 1995; 38: 487-93.
4. 4 Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-44.
5. 5 Hanefeld M, Fischer S, Julius U et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-83.
6. 6 Scandinavian Simvastatin Survival Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994; 344: 1383-89.
7. 7 Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009.
8. 8 Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-307.
9. 9 Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614-20.
10. 10 Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-63.
11. 11 Assmann G, Schulte H, von Eckavdstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77: 1179-84.
12. 12 Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-19.
13. 13 Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998; 97: 1029-36.
14. 14 Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992; 70: 3-9H.
15. 15 Fontbonne A, Eschwege E, Cambien F et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989; 32: 300-304.
16. 16 Turner RC, Millns H, Neil AW et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS. 23). Br Med J 1998; 316: 823-28.
17. 17 Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996; 124: 136-45.
18. 18 Davignon J. Fibrates: a review of important issues and recent findings. Can J Cardiol 1994; 10: 61-71B.
19. 19 Sirtori CR, Franceschini G. Effects of fibrates on serum lipids and atherosclerosis. Pharmacol Ther 1988; 37: 167-91.
20. 20 Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347: 849-53.
21. 21 Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996; 37: 907-25.
22. 22 Hertz R, Bishara SJ, Bar TJ. Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J Biol Chem 1995; 270: 13 470-75.
23. 23 Shviro I, Leitersdorf E. Targeted prevention of coronary artery disease: pharmacological considerations in multi-modality treatment. Cardiology 1996; 87: 469-75.
24. 24 Pasternak RC, Brown LE, Stone PH, Silverman DI, Gibson CM, Sacks FM. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and 'normal' cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group. Ann Intern Med 1996; 125: 529-40.
25. 25 Lipid Research Clinics. Lipid and lipoprotein analysis. Manual of Laboratory Operations, vol. 1. NIH publication 75-268. Bethesda, MD: US Department of Health, Education and Welfare, 1975.
26. 26 Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989; 80: 1313-19.
27. 27 Branchi A, Rovellini A, Sommariva D, Gugliandolo AG, Fasoli A. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb Haemost 1993; 70: 241-43.
28. 28 Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. J Am Med Assoc 1990; 264: 71-75.